Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Chief Technology Officer | December 15, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kyverna Therapeutics, Inc.
Report date December 15, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,636 |
Ending reported balance
After 2025-12-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-15 · Exercise / conversion · Acquired 23,998 · Balance 46,634 F1: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions. Row 2 · 2025-12-15 · Sale · Disposed 23,998 · Balance 22,636 F1: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | 85,865 |
Reported balance
After 2025-12-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-15 · Exercise / conversion · Disposed 23,998 · Balance 85,865 F1: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions. F2: 25% of the original number of shares subject to the option vested on January 1, 2025, and 1/48th of the original number of shares subject to the option vests in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions.
F2: 25% of the original number of shares subject to the option vested on January 1, 2025, and 1/48th of the original number of shares subject to the option vests in monthly installments thereafter, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2025 Filed Dec 18, 2025 01:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionStock option (right to buy) · Derivative | 23,998 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001193125-25-323332 · ownership.xml · derivative · entry 3 Walker Karen Marie · CIK 0002008556 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,865 Underlying: Common Stock · 23,998 shares Expires 2033-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions. F2 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on January 1, 2025, and 1/48th of the original number of shares subject to the option vests in monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 01:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | SaleCommon Stock | 23,998 | $12.20 | $292,775.60 |
DisclosureSEC source: 0001193125-25-323332 · ownership.xml · nonDerivative · entry 2 Walker Karen Marie · CIK 0002008556 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,636 F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 01:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionCommon Stock | 23,998 | $4.83 | $115,910.34 |
DisclosureSEC source: 0001193125-25-323332 · ownership.xml · nonDerivative · entry 1 Walker Karen Marie · CIK 0002008556 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 21:40 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-054342 · ownership.xml · nonDerivative · entry 1 Walker Karen Marie · CIK 0002008556 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,636 F1 · shares: Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:56 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,636 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000950170-24-071493 · ownership.xml · derivative · entry 2 Walker Karen Marie · CIK 0002008556 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,648 Underlying: Common Stock · 9,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the original number of shares subject to the option vested on September 13, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter. F1 · derivative.expiration_date: 25% of the original number of shares subject to the option vested on September 13, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:56 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | Exercise / conversionCommon Stock | 9,636 | $4.42 | $42,591.12 |
DisclosureSEC source: 0000950170-24-071493 · ownership.xml · nonDerivative · entry 1 Walker Karen Marie · CIK 0002008556 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 25% of the original number of shares subject to the option vested on September 13, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter. Read SEC document |
| April 11, 2024 Filed Apr 15, 2025 21:40 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0000950170-25-054342 · ownership.xml · derivative · entry 2 Walker Karen Marie · CIK 0002008556 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-04-11 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.